BiotechTube

Technetium Tc99m Sestamibi

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2, Coronary Restenosis

Trial Timeline

Apr 1, 2004 → Dec 1, 2005

NCT ID
NCT00162357

About Technetium Tc99m Sestamibi

Technetium Tc99m Sestamibi is a approved stage product being developed by Lantheus Holdings for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT00162357. Target conditions include Diabetes Mellitus, Type 2, Coronary Restenosis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (4)

NCT IDPhaseStatus
NCT00162045Phase 1/2Completed
NCT00162331ApprovedCompleted
NCT00162357ApprovedCompleted
NCT00162344ApprovedCompleted

Competing Products

20 competing products in Diabetes Mellitus, Type 2

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Lantheus Holdings

Piflufolastat F 18 Intravenous Solution [PYLARIFY]Approved
82
3D HI and SHI of UCAApproved
82
Definity® Vial for (Perflutren Lipid Microsphere) Injectable SuspensionApproved
82
DefinityApproved
82
Perflutren Lipid Microsphere Injectable SuspensionApproved
82